Qualigen Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
AIxCrypto Holdings reported a $17.0M 2025 net loss, rebranded from Qualigen, raised $41M, built a $10.3M crypto treasury, and narrowed its strategy to real‑world asset tokenization and embodied AI while warning of going concern risks and heavy dilution.
Qualigen Therapeutics, an early-clinical-stage oncology company, reported a significant net loss and accumulated deficit for 2024, raising substantial doubt about its ability to continue as a going concern, compounded by a Nasdaq delisting notice and a slowdown in its core therapeutic programs.
Qualigen Therapeutics reports its full year 2023 results, highlighting a strategic shift towards therapeutics and away from diagnostics, while facing financial challenges.